Clinical trials: Cancer Care Providers
- Condition Cancer Care Providers
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Melanoma, Herpetic Infection
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients…
- Trial name
- NCT02910557
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 187 people
- Sponsor
- Amgen